^
No biomarker
GBM
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 1wk
TNFA overexpression
GBM
bevacizumab
Resistant
:
C3
Acta Neuropathol Commun - 3wk
VEGFA overexpression
GBM
bevacizumab
Resistant
:
D
Biomolecules - 3wk
IDH1 overexpression
GBM
bevacizumab
Resistant
:
D
Biomolecules - 3wk
No biomarker
GBM
Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Brain Cancer
lomustine
Sensitive
:
A1
No biomarker
Astrocytoma
everolimus
Sensitive
:
A1
No biomarker
Astrocytoma
carmustine
Sensitive
:
A1
No biomarker
Ependymoma
carmustine
Sensitive
:
A1
No biomarker
Medulloblastoma
carmustine
Sensitive
:
A1
No biomarker
Anaplastic Astrocytoma
temozolomide
Sensitive
:
A1
No biomarker
GBM
bevacizumab
Sensitive
:
A1
No biomarker
Glioma
carmustine
Sensitive
:
A1
No biomarker
GBM
temozolomide
Sensitive
:
A1
No biomarker
GBM
carmustine
Sensitive
:
A1
No biomarker
GBM
Zirabev (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
GBM
Mvasi (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
GBM
PCV
Sensitive
:
A2
No biomarker
Anaplastic Astrocytoma
PCV
Sensitive
:
A2
No biomarker
Glioma
PCV
Sensitive
:
A2
MGMT promoter methylation
GBM
temozolomide
Sensitive
:
A2
No biomarker
Oligodendroglioma
temozolomide
Sensitive
:
A2
No biomarker
Glioma
temozolomide
Sensitive
:
A2
No biomarker
Meningioma
bevacizumab + everolimus
Sensitive
:
A2
No biomarker
Meningioma
bevacizumab
Sensitive
:
A2
No biomarker
Meningioma
sunitinib
Sensitive
:
A2
No biomarker
Medulloblastoma
cisplatin + cyclophosphamide oral + vincristine
Sensitive
:
A2
No biomarker
Medulloblastoma
cisplatin + vincristine + lomustine
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our